GlassScriptPhysician profile
Seth Gottlieb
NPI 1003810763
$4,474.77
in general payments reported to CMS, 2019-2025
29 companies · $903 in 2025
The $903 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.00 · 2020: $309 · 2021: $531 · 2022: $698 · 2023: $1,191 · 2024: $764 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,858.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,857.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,545.83 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $506.77 | 2020-2025 | Fasenra, Airsupra |
| Vapotherm INC | $259.21 | 2019-2024 | Vapotherm |
| Viiv Healthcare Company | $232.14 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $228.76 | 2021-2024 | Opsumit, Uptravi |
| Amgen INC. | $201.03 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $195.06 | 2023-2024 | Glassia |
| Verona Pharma, INC. | $164.01 | 2025 | Ohtuvayre |
| Olympus America INC. | $150.00 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.90 | 2021-2025 | Jascayd, Ofev |
| Mylan Specialty L.P. | $112.82 | 2023-2024 | Yupelri |
| Pfizer INC. | $109.42 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.89 | 2020-2023 | |
| Insmed, INC. | $87.05 | 2025 | Arikayce, Brinsupri |
| Ani Pharmaceuticals, INC. | $60.10 | 2023 | Purified Cortrophin Gel |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $50.59 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $48.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $47.80 | 2020-2025 | Winrevair |
| Fisher & Paykel Healthcare INC | $39.57 | 2022 | |
| Inogen, INC. | $30.32 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Abbvie INC. | $26.85 | 2021 | |
| Electromed, INC. | $22.83 | 2025 | Smartvest |
| Pulmonx Corporation | $22.26 | 2023 | Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Grifols USA, LLC | $21.92 | 2023 | Prolastin-C Liquid |
| Philips North America LLC | $21.66 | 2025 | Vest Therapy Und |
| Eagle Pharmaceuticals, INC. | $20.52 | 2023 | |
| Celgene Corporation | $15.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.72 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Gottlieb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.